These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 12519856)

  • 1. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects.
    Vilsbøll T; Agersø H; Krarup T; Holst JJ
    J Clin Endocrinol Metab; 2003 Jan; 88(1):220-4. PubMed ID: 12519856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
    Vilsbøll T; Krarup T; Madsbad S; Holst JJ
    Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
    Vilsbøll T; Krarup T; Sonne J; Madsbad S; Vølund A; Juul AG; Holst JJ
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2706-13. PubMed ID: 12788877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
    Vilsbøll T; Toft-Nielsen MB; Krarup T; Madsbad S; Dinesen B; Holst JJ
    Diabetes Care; 2000 Jun; 23(6):807-12. PubMed ID: 10841001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions.
    Gutniak MK; Larsson H; Sanders SW; Juneskans O; Holst JJ; Ahrén B
    Diabetes Care; 1997 Dec; 20(12):1874-9. PubMed ID: 9405910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes.
    Meier JJ; Gallwitz B; Salmen S; Goetze O; Holst JJ; Schmidt WE; Nauck MA
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2719-25. PubMed ID: 12788879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.
    Vilsbøll T; Krarup T; Deacon CF; Madsbad S; Holst JJ
    Diabetes; 2001 Mar; 50(3):609-13. PubMed ID: 11246881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No hypoglycemia after subcutaneous administration of glucagon-like peptide-1 in lean type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitis.
    Knop FK; Vilsbøll T; Larsen S; Madsbad S; Holst JJ; Krarup T
    Diabetes Care; 2003 Sep; 26(9):2581-7. PubMed ID: 12941722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose.
    Vilsbøll T; Krarup T; Madsbad S; Holst JJ
    Diabet Med; 2001 Feb; 18(2):144-9. PubMed ID: 11251679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.
    Nauck MA; Niedereichholz U; Ettler R; Holst JJ; Orskov C; Ritzel R; Schmiegel WH
    Am J Physiol; 1997 Nov; 273(5):E981-8. PubMed ID: 9374685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state.
    Egan JM; Meneilly GS; Habener JF; Elahi D
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3768-73. PubMed ID: 12161508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans.
    Quddusi S; Vahl TP; Hanson K; Prigeon RL; D'Alessio DA
    Diabetes Care; 2003 Mar; 26(3):791-8. PubMed ID: 12610039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
    Hücking K; Kostic Z; Pox C; Ritzel R; Holst JJ; Schmiegel W; Nauck MA
    Diabet Med; 2005 Apr; 22(4):470-6. PubMed ID: 15787675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
    Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.
    Todd JF; Edwards CM; Ghatei MA; Mather HM; Bloom SR
    Clin Sci (Lond); 1998 Sep; 95(3):325-9. PubMed ID: 9730852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.
    Vollmer K; Holst JJ; Baller B; Ellrichmann M; Nauck MA; Schmidt WE; Meier JJ
    Diabetes; 2008 Mar; 57(3):678-87. PubMed ID: 18057091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers.
    Nauck MA; Heimesaat MM; Behle K; Holst JJ; Nauck MS; Ritzel R; Hüfner M; Schmiegel WH
    J Clin Endocrinol Metab; 2002 Mar; 87(3):1239-46. PubMed ID: 11889194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.
    Rachman J; Barrow BA; Levy JC; Turner RC
    Diabetologia; 1997 Feb; 40(2):205-11. PubMed ID: 9049482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes.
    Toft-Nielsen MB; Madsbad S; Holst JJ
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3853-60. PubMed ID: 11502823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-like peptide (GLP)-1 and leptin concentrations in obese patients with Type 2 diabetes mellitus.
    Mannucci E; Ognibene A; Cremasco F; Bardini G; Mencucci A; Pierazzuoli E; Ciani S; Fanelli A; Messeri G; Rotella CM
    Diabet Med; 2000 Oct; 17(10):713-9. PubMed ID: 11110504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.